u/Buy-NVDA — thesis ledger

Window	Theses	Resolved	Wins	Win rate	Avg return	Median return
1d	1	1	0	0%	-2.0%	-2.0%
3d	1	1	1	100%	+1.3%	+1.3%
1w	1	1	0	0%	-6.4%	-6.4%
1m	1	1	0	0%	-8.3%	-8.3%
3m	1	1	1	100%	+37.2%	+37.2%
6m	0	0	0	—	—	—
1y	0	0	0	—	—	—

Window

Theses

Resolved

Wins

Win rate

Avg return

Median return

-2.0%

100%

+1.3%

-6.4%

-8.3%

100%

+37.2%

—

Thesis history

$VRDNr/wallstreetbetsDDbullish

u/Buy-NVDA · 121d agono track record yet

Ez money VRDN

Viridian Therapeutics released Phase 3 data for TED showing strong efficacy (p < 0.0001) with a potentially best-in-class safety profile versus Amgen's Tepezza. With $1.1B in cash, institutional backing at $17.00, and a June 30 PDUFA decision as a near-term catalyst, the stock—currently trading below the offering price—has upside to analyst targets of $34+.

At post $17.20Now $23.17+34.7% since postedas of Sep 8, 4:31 PM ET

1d-2.0%

3d+1.3%

1w-6.4%

1m-8.3%

3m+37.2%

6m—

1y—

original post →

End of results.